- Home
- ABEO vs KAZR Comparison
ABEO vs KAZR Comparison
Compare ABEO & KAZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SELL
Current Price
$4.90
SELL
Current Price
$2.14
Company Overview
Basic Information| Metric | ABEO | KAZR |
|---|---|---|
| Founded | 1974 | 2024 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.5M | 398.1M |
| IPO Year | 2005 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ABEO | KAZR |
|---|---|---|
| Price | $4.90 | $2.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $18.88 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 273.1K |
| Earning Date | 11-11-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $804.33 | N/A |
| Revenue Next Year | $119.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $1.60 |
| 52 Week High | $7.65 | $3.20 |
Technical Indicators
Market Signals| Indicator | ABEO | KAZR |
|---|---|---|
| Relative Strength Index (RSI) | 32.84 | 42.57 |
| Support Level | $4.23 | $1.71 |
| Resistance Level | $5.36 | $2.35 |
| Average True Range (ATR) | 0.19 | 0.24 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 5.74 | 4.61 |
Price Performance
Historical Comparison ABEO
KAZR
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.